Navigation Links
Umbilical cord blood cell therapy in an animal model of Alzheimer's disease

New Rochelle, NY, March 26, 2008A novel strategy based on targeted immune suppression using human umbilical cord blood cells may improve the pathology and cognitive decline associated with Alzheimers disease, based on the results of a study in a mouse model of this currently untreatable neurodegenerative condition, as described in a groundbreaking report in Stem Cells and Development (, a peer-reviewed journal published by Mary Ann Liebert, Inc ( The paper will be available free online (

Following a series of low-dose infusions of human umbilical cord blood cells into mice with Alzheimers-like disease, the amount of amyloid- and -amyloid plaqueshallmarks of Alzheimers pathology in the brainwas markedly reduced. Amyloid- induces an inflammatory response in the brain associated with the interaction of CD40 and CD40L, two pro-inflammatory molecules.

Human umbilical cord blood cell therapy was associated with suppression of CD40-CD40L activity, suggesting that this therapeutic approach modulates the activity of the immune system, offering the potential to target the pathogenic inflammatory response that may contribute to a variety of degenerative conditions, including Alzheimers disease.

Jun Tan, PhD, MD, and colleagues from USF (Tampa), Yale University (New Haven, CT), Cedars-Sinai Medical Center (Los Angeles, CA), Saneron CCEL Therapeutics (Tampa, FL), and Saitama Medical School (Japan), concluded that human umbilical cord blood cell-induced disruption of the CD40-CD40L interaction may alleviate the key pathologic changes in the brain associated with Alzheimers disease in a report entitled, Peripherally administered human umbilical cord blood cells reduce parenchymal and vascular beta-amyloid deposits in Alzheimer mice.

Previously, challenging observations have reported phenomena suggesting the non-hematologic therapeutic potential of blood stem cells. What is novel about this paper is its application to Alzheimers disease, and a significant advance in characterizing the ameliorative mechanism of action says Graham C. Parker, PhD, Editor-in-Chief of Stem Cells and Development, and a research professor in The Carman and Ann Adams Department of Pediatrics, Wayne State University School of Medicine, Children's Hospital of Michigan.


Contact: Vicki Cohn
Mary Ann Liebert, Inc./Genetic Engineering News

Related biology news :

1. Blood vessel protein reverses macular degeneration, diabetic retinopathy in mice
2. Diabetes makes it hard for blood vessels to relax
3. Weill Cornell team discovers how brains own tPA helps regulate blood flow to neurons
4. High blood pressure in older adults traced to genes effects in blood vessels
5. Eltrombopag effective for hepatitis C patients with low blood-platelet counts
6. MIT works toward engineered blood vessels
7. Blood pressure drug telmisartan shows powerful activity against stroke
8. Protein controls blood vessel formation, offers new drug target
9. Looking through the eyes of a mouse, scientists monitor circulating cells in its bloodstream
10. Study of malaria parasite in patient blood finds distinct physiological states
11. Blood clotting protein linked to rheumatoid arthritis
Post Your Comments:
(Date:11/12/2015)...   Growing need for low-cost, easy to ... paving the way for use of biochemical sensors ... in clinical, agricultural, environmental, food and defense applications. ... medical applications, however, their adoption is increasing in ... emphasis on improving product quality and growing need ...
(Date:11/9/2015)... 2015  Synaptics Inc. (NASDAQ: SYNA ), the ... entry into the automotive market with a comprehensive and ... of consumer electronics human interface innovation. Synaptics, industry-leading touch ... the automotive industry and will be implemented in numerous ... , Japan , and ...
(Date:10/29/2015)... , Oct. 29, 2015 Daon, a ... that it has released a new version of its ... in North America have already ... v4.0 also includes a FIDO UAF certified server ... already preparing to activate FIDO features. These customers include ...
Breaking Biology News(10 mins):
(Date:11/24/2015)... 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:  AEZS) ... remaining 11,000 post-share consolidation (or 1,100,000 pre-share consolidation) ... B Warrants") subject to the previously disclosed November ... 2015, which will result in the issuance of ... the issuance of such shares, there will be ...
(Date:11/24/2015)... ... 24, 2015 , ... InSphero AG, the leading supplier of easy-to-use solutions for ... Aregger to serve as Chief Operating Officer. , Having joined InSphero in ... and was promoted to Head of InSphero Diagnostics in 2014. There she ...
(Date:11/24/2015)... LOS ANGELES , Nov. 24, 2015 ... a biotechnology company focused on the discovery, development and ... Marban , Ph.D., Chief Executive Officer, is scheduled to ... December 1, 2015 at 10:50 a.m. EST, at The ... York City . . ...
(Date:11/24/2015)... and NEW YORK , November 24, 2015 ... by Bristol-Myers Squibb in a European ... Squibb Company in which the companies will work closely ... and other areas of unmet medical need. The collaboration is ... 5, the latest LSP fund. This is the first investment ...
Breaking Biology Technology: